AU
CA
NZ
UK
US
IND
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 Low-Volatility Stocks Facing Headwinds
Fri 16 May 25, 04:36 AMHere's Why Labcorp (LH) is a Strong Momentum Stock
Thu 15 May 25, 01:50 PMZacks Industry Outlook Highlights Cardinal Health, Labcorp and Align Technology
Wed 14 May 25, 12:09 PMLH Q1 Earnings Call: Labcorp Grows Revenue but Misses Expectations, Raises Adjusted EPS Guidance
Tue 13 May 25, 10:22 AMShould Value Investors Buy Labcorp (LH) Stock?
Mon 12 May 25, 01:40 PM1 Healthcare Stock with Competitive Advantages and 2 to Brush Off
Fri 09 May 25, 04:37 AMLabcorp to Webcast Its Annual Meeting of Shareholders May 15
Thu 08 May 25, 08:15 PM1 Profitable Stock That Stand Out and 2 to Turn Down
Thu 08 May 25, 04:35 AMLabcorp Holdings' (NYSE:LH) Earnings May Just Be The Starting Point
Wed 07 May 25, 11:18 AMQ1 2025 OPKO Health Inc Earnings Call
Thu 01 May 25, 12:57 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 1582.60M | 3126.60M | 2219.10M | 1104.90M | 1268.30M |
| Minority interest | -1.50000M | -2.20000M | 20.70M | 20.10M | 0.20M |
| Net income | 1279.10M | 2377.30M | 1556.10M | 823.80M | 883.70M |
| Selling general administrative | 1996.60M | 1952.10M | 1729.00M | 1624.50M | 1570.90M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 4385.10M | 5624.30M | 4952.80M | 3252.50M | 3176.40M |
| Reconciled depreciation | 633.90M | 745.10M | 624.70M | 577.20M | 552.10M |
| Ebit | 1773.90M | 3259.50M | 2445.40M | 1330.20M | 1553.10M |
| Ebitda | 2743.20M | 4116.70M | 3543.60M | 1968.60M | 2105.20M |
| Depreciation and amortization | 969.30M | 857.20M | 1098.20M | 638.40M | 552.10M |
| Non operating income net other | - | 79.20M | - | - | 186.80M |
| Operating income | 1773.90M | 3259.50M | 2445.40M | 1330.20M | 1325.70M |
| Other operating expenses | 12747.60M | 12818.30M | 11030.40M | 10170.00M | 9959.60M |
| Interest expense | 180.30M | 212.10M | 207.40M | 240.70M | 244.20M |
| Tax provision | 302.00M | 747.10M | 662.10M | 280.00M | 384.40M |
| Interest income | 166.00M | 175.40M | 194.20M | 212.30M | 225.10M |
| Net interest income | -180.30000M | -212.10000M | -207.40000M | -240.70000M | -244.20000M |
| Extraordinary items | - | - | - | - | -44.90000M |
| Non recurring | - | 43.10M | - | - | 48.10M |
| Other items | - | - | - | - | - |
| Income tax expense | 302.00M | 747.10M | 662.10M | 280.00M | 384.40M |
| Total revenue | 14876.80M | 16120.90M | 13978.50M | 11554.80M | 11333.40M |
| Total operating expenses | 2255.90M | 2321.70M | 2004.70M | 1867.70M | 1802.60M |
| Cost of revenue | 10491.70M | 10496.60M | 9025.70M | 8302.30M | 8157.00M |
| Total other income expense net | -191.30000M | -132.90000M | -226.30000M | -225.30000M | 138.70M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1280.60M | 2379.50M | -0.90000M | 824.90M | 883.90M |
| Net income applicable to common shares | 1279.10M | 2377.30M | -0.90000M | 823.80M | 883.70M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 20155.10M | 20385.40M | 20071.70M | 18021.40M | 16185.30M |
| Intangible assets | 3946.90M | 3735.50M | 3961.10M | 4034.50M | 3911.10M |
| Earning assets | - | - | - | - | - |
| Other current assets | 707.00M | 478.10M | 364.80M | 373.70M | 309.00M |
| Total liab | 10058.50M | 10112.50M | 10712.00M | 10454.40M | 9213.90M |
| Total stockholder equity | 10096.60M | 10272.90M | 9359.70M | 7567.00M | 6971.40M |
| Deferred long term liab | - | 762.90M | - | - | 940.00M |
| Other current liab | 1068.80M | 1404.10M | 1357.70M | 942.40M | 870.00M |
| Common stock | 8.10M | 8.50M | 9.00M | 9.00M | 11.70M |
| Capital stock | 8.10M | 8.50M | 9.00M | 9.00M | 11.70M |
| Retained earnings | 10581.70M | 10456.40M | 9402.30M | 7903.60M | 7079.80M |
| Other liab | 1079.30M | 1165.40M | 1431.80M | 1326.00M | 1274.00M |
| Good will | 8121.00M | 7958.90M | 7751.50M | 7865.00M | 7360.30M |
| Other assets | 440.30M | 484.20M | 350.90M | 356.50M | 277.70M |
| Cash | 430.00M | 1472.70M | 1320.80M | 337.50M | 426.80M |
| Cash and equivalents | 430.00M | 1472.70M | 1320.80M | 337.50M | 426.80M |
| Total current liabilities | 3078.50M | 2782.90M | 3078.50M | 2646.80M | 1878.90M |
| Current deferred revenue | 582.10M | 558.50M | 506.50M | 451.00M | 356.40M |
| Net debt | 5864.90M | 4869.90M | 5435.60M | 6745.10M | 5633.00M |
| Short term debt | 492.80M | 199.00M | 575.40M | 621.10M | 17.90M |
| Short long term debt | 301.30M | 1.50M | 376.70M | 415.20M | 10.00M |
| Short long term debt total | 6294.90M | 6342.60M | 6756.40M | 7082.60M | 6059.80M |
| Other stockholder equity | -493.20000M | -192.00000M | 110.30M | 26.80M | 343.00M |
| Property plant equipment | 2956.20M | 2815.40M | 2809.30M | 2724.30M | 1784.70M |
| Total current assets | 4625.00M | 5330.50M | 5125.40M | 2981.20M | 2835.40M |
| Long term investments | 65.70M | 60.90M | 73.50M | 84.90M | 60.50M |
| Net tangible assets | -1971.30000M | -1421.50000M | -2352.90000M | -4332.50000M | -4300.00000M |
| Short term investments | - | - | 73.00M | 9.10M | - |
| Net receivables | 3017.40M | 2978.30M | 3016.60M | 2025.30M | 1862.30M |
| Long term debt | 5038.80M | 5416.50M | 5419.00M | 5789.80M | 6041.90M |
| Inventory | 470.60M | 401.40M | 423.20M | 244.70M | 237.30M |
| Accounts payable | 934.80M | 621.30M | 638.90M | 632.30M | 634.60M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 20.60M | - | - | 19.10M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -493.20000M | -192.00000M | -161.90000M | -372.40000M | -463.10000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 8.50M | 9.00M | 9.00M | 11.70M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 10456.80M | - | - | 7079.80M |
| Treasury stock | - | - | - | - | -1108.10000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 432.70M | 462.60M | 410.00M | 435.40M | 231.60M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 15530.10M | 15054.90M | 14946.30M | 15040.20M | 13349.90M |
| Capital lease obligations | 954.80M | 924.60M | 960.70M | 902.60M | 58.90M |
| Long term debt total | 5122.40M | 5501.10M | 5503.40M | 5880.90M | 6041.90M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1652.20000M | -14.60000M | -643.20000M | -1283.10000M | -4.00000M |
| Change to liabilities | 342.40M | 34.80M | 43.10M | 25.30M | 37.30M |
| Total cashflows from investing activities | -1652.20000M | -884.60000M | -643.20000M | -1283.10000M | 206.70M |
| Net borrowings | - | -375.00000M | -412.20000M | 210.10M | -409.30000M |
| Total cash from financing activities | -1322.20000M | -2065.80000M | -517.40000M | -252.70000M | -1389.90000M |
| Change to operating activities | -816.20000M | -344.10000M | 252.50M | -174.70000M | -30.10000M |
| Net income | 1280.60M | 2379.50M | 1557.00M | 824.90M | 883.90M |
| Change in cash | -1042.70000M | 151.90M | 983.30M | -89.30000M | 110.20M |
| Begin period cash flow | 1472.70M | 1320.80M | 337.50M | 426.80M | 316.60M |
| End period cash flow | 430.00M | 1472.70M | 1320.80M | 337.50M | 426.80M |
| Total cash from operating activities | 1955.90M | 3109.60M | 2135.30M | 1444.70M | 1305.40M |
| Issuance of capital stock | 50.60M | 51.70M | 55.90M | 64.70M | 69.10M |
| Depreciation | 633.90M | 745.10M | 624.70M | 577.20M | 552.10M |
| Other cashflows from investing activities | -1170.30000M | -424.20000M | 3.10M | 1.70M | 590.50M |
| Dividends paid | -195.20000M | -1000.00000M | -151.70000M | -2395.00000M | 467.20M |
| Change to inventory | -45.50000M | 2.80M | -196.60000M | -21.90000M | -18.90000M |
| Change to account receivables | 15.90M | 222.00M | -913.40000M | -64.10000M | 50.20M |
| Sale purchase of stock | -1100.00000M | -1668.50000M | -100.00000M | -450.00000M | -700.00000M |
| Other cashflows from financing activities | 709.80M | 1926.00M | 242.30M | 4712.50M | 880.00M |
| Change to netincome | 646.30M | 56.00M | 611.10M | 144.00M | -60.50000M |
| Capital expenditures | 481.90M | 460.40M | 381.70M | 400.20M | 379.80M |
| Change receivables | - | - | - | - | -30.80000M |
| Cash flows other operating | - | - | - | - | -57.70000M |
| Exchange rate changes | - | - | - | - | -12.00000M |
| Cash and cash equivalents changes | - | - | - | - | 110.20M |
| Change in working capital | -603.40000M | -263.70000M | -856.90000M | -294.40000M | -70.30000M |
| Stock based compensation | 144.10M | 153.70M | 111.70M | 107.00M | 91.60M |
| Other non cash items | 482.40M | 170.90M | 745.80M | 200.80M | -174.10000M |
| Free cash flow | 1474.00M | 2649.20M | 1753.60M | 1044.50M | 925.60M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LH Laboratory Corporation of America Holdings |
-4.91 1.79% | 268.70 | 23.09 | 15.17 | 1.25 | 2.37 | 1.61 | 12.59 |
| TMO Thermo Fisher Scientific Inc |
-9.89 1.94% | 500.08 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-3.58 1.80% | 195.22 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
-1.21 1.04% | 115.43 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
-11.6 1.90% | 598.85 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
358 South Main Street, Burlington, NC, United States, 27215
| Name | Title | Year Born |
|---|---|---|
| Mr. Adam H. Schechter | Pres, CEO & Chairman | 1965 |
| Mr. Glenn A. Eisenberg | CFO & Exec. VP | 1961 |
| Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH | Exec. VP, Pres of Diagnostics & Chief Medical Officer | 1974 |
| Mr. Mark S. Schroeder | Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain | 1961 |
| Dr. Paul R. Kirchgraber M.D. | Exec. VP & CEO of Covance Drug Devel. | 1962 |
| Dr. Michelle Abelson Ph.D. | Laboratory Director of Operations | NA |
| Mr. Peter J. Wilkinson | Sr. VP & Chief Accounting Officer | 1972 |
| Mr. Lance V. Berberian | Exec. VP and Chief Information & Technology Officer | 1963 |
| Dr. Marcia T. Eisenberg Ph.D. | Chief Scientific Officer & Sr. VP | 1960 |
| Chas Cook | VP of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...